- Location UK
- Title Mitochondrial MT‑RNR1 and the risk of AIHL
Why do aminoglycosides both “save lives” and sometimes cause permanent hearing loss?
Aminoglycosides (such as gentamicin, amikacin, and tobramycin) kill bacteria by binding to bacterial ribosomes (involving rRNA in the decoding region), disrupting accurate protein synthesis so severely that bacterial cells fail. The key issue is that, in some individuals with specific genetic variants, the human target becomes more “bacteria‑like,” making it easier for aminoglycosides to bind inappropriately and damage inner‑ear structures—sometimes even after a standard dose or a single dose
Project focus
In CPIC’s guideline, mitochondrial MT‑RNR1 variants are treated as a major genetic driver of susceptibility to aminoglycoside‑induced hearing loss (AIHL). The molecular rationale described is that these variants can make human mitochondrial 12S rRNA more similar to bacterial 16S rRNA, enabling aminoglycosides to bind more readily to human ribosomes and trigger ototoxicity.
CPIC’s strong recommendation: Avoid aminoglycosides in carriers of high‑risk MT‑RNR1 variants
A highly actionable (implementation‑friendly) conclusion from CPIC is a clear prescribing recommendation: avoid aminoglycosides in individuals who carry MT‑RNR1 variants associated with increased AIHL risk. The only exception is the rare scenario in which no safe or effective alternative therapy exists, and the risk of undertreated infection outweighs the increased risk of permanent hearing loss. This recommendation applies to the entire aminoglycoside class because evidence is insufficient to differentiate risk between individual drugs within the class
Implementation implications: turning a guideline into a clinical pathway
If we treat this as an applied research program, the real “impact multiplier” is implementation: when hospitals integrate MT‑RNR1 testing into routine workflows, they should design a clinical pathway so clinicians can act quickly—if a high‑risk variant is detected, the system supports avoiding aminoglycosides and switching to safer alternatives (when available). This is particularly important for young children, where hearing loss can have long‑lasting consequences for language development.
Short conclusion
CPIC is converting pharmacogenomic evidence into practical, deployable guidance to prevent a severe but avoidable adverse outcome: permanent aminoglycoside‑related hearing loss. With MT‑RNR1, the research story is not only about discovering a gene–drug association, but also about operationalizing that discovery into safer prescribing decisions—especially in settings where aminoglycosides remain widely used
